Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OCS-05 +SoC · OCS-05

Small molecule · developed by Oculis

Phase 2 Most advanced trial (none active)
OCS Developer
1 Registered trials

What is OCS-05 +SoC?

OCS-05 is an agent given intravenously for five consecutive days together with standard of care corticosteroid treatment. It is studied in optic neuritis, an inflammatory disease of the optic nerve.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OCS-05
Drug type
Small molecule
Therapy area
Ophthalmology
Developer
Oculis (OCS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04762017 Phase 2 Optic Neuritis Completed OCS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Optic Neuritis

More from Oculis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the OCS page.

Follow OCS, the company behind OCS-05 +SoC

See OCS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.